Cytokines in the Treatment of Cancer.

Cytokines are major regulators of innate and adaptive immunity that enable cells of the immune system to communicate over short distances. Cytokine therapy to activate the immune system of cancer patients has been an important treatment modality and continues to be a key contributor to current clinical cancer research. Interferon alpha (IFNα) is approved for adjuvant treatment of completely resected high-risk melanoma patients and several refractory malignancies. High-dose interleukin-2 (HDIL-2) is approved for treatment of metastatic renal cell cancer and melanoma, but both agents are currently less commonly used with the development of newer agents. Granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN gamma (IFNγ), IL-7, IL-12, and IL-21 were evaluated in clinical trials and remain part of certain investigational trials. The initial single-agent clinical trials with the long-awaited IL-15 have been completed and combination trials with antitumor antibodies or checkpoint inhibitors (CPIs) have been initiated. However, cytokines in monotherapy have not fulfilled the promise of efficacy seen in preclinical experiments. They are often associated with severe dose-limiting toxicities that are manageable with appropriate dosing and are now better understood to induce immune-suppressive humoral factors, suppressive cells, and cellular checkpoints, without consistently inducing a tumor-specific response. To circumvent these impediments, cytokines are being investigated clinically with new engineered cytokine mutants (superkines), chimeric antibody-cytokine fusion proteins (immunokines), anticancer vaccines, CPIs, and cancer-directed monoclonal antibodies to increase their antibody-dependent cellular cytotoxicity or sustain cellular responses and anticancer efficacy. In this review, we summarize current knowledge and clinical application of cytokines either as monotherapy or in combination with other biological agents. We emphasize a discussion of future directions for research on these cytokines, to bring them to fruition as major contributors for the treatment of metastatic malignancy.

[1]  M. Donia,et al.  Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma , 2015, Human vaccines & immunotherapeutics.

[2]  T. Waldmann,et al.  Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates. , 2010, Blood.

[3]  T. Waldmann,et al.  Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model , 2012, Proceedings of the National Academy of Sciences.

[4]  M. Collins,et al.  IL-21 Activates Both Innate and Adaptive Immunity to Generate Potent Antitumor Responses that Require Perforin but Are Independent of IFN-γ1 , 2003, The Journal of Immunology.

[5]  C. Slingluff,et al.  Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma , 2014, Journal of Immunotherapy for Cancer.

[6]  D. Raulet,et al.  Cytokine treatment in cancer immunotherapy , 2015, Oncotarget.

[7]  T. Waldmann,et al.  Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action1 , 2008, The Journal of Immunology.

[8]  M Aguet,et al.  Functional role of type I and type II interferons in antiviral defense. , 1994, Science.

[9]  K. Garcia,et al.  Structure of the Quaternary Complex of Interleukin-2 with Its α, ß, and γc Receptors , 2005, Science.

[10]  H. Ihn,et al.  Phase II study of i.v. interferon‐gamma in Japanese patients with mycosis fungoides , 2014, The Journal of dermatology.

[11]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[12]  Jian-xin Lin,et al.  IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. , 2011, Current opinion in immunology.

[13]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[14]  J. Laszlo,et al.  The role of interferon in cancer therapy: A current perspective , 1988, CA: a cancer journal for clinicians.

[15]  M. Lenardo.  Fas and the art of lymphocyte maintenance , 1996, The Journal of experimental medicine.

[16]  K. Margolin,et al.  Cytokines in Cancer Immunotherapy , 2011, Cancers.

[17]  K. Rajewsky,et al.  Development and proliferation of lymphocytes in mice deficient for both interleukins‐2 and ‐4 , 1994, European journal of immunology.

[18]  M. Roberti,et al.  IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR , 2011, Breast Cancer Research and Treatment.

[19]  T. Waldmann,et al.  Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities , 2010, Proceedings of the National Academy of Sciences.

[20]  S. Pestka,et al.  Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. , 1980, Annals of internal medicine.

[21]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[22]  T. Waldmann,et al.  Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer , 2009, Proceedings of the National Academy of Sciences.

[23]  W. Leonard,et al.  Interleukin-21: basic biology and implications for cancer and autoimmunity. , 2008, Annual review of immunology.

[24]  H. Hausmaninger,et al.  Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial , 2000, British Journal of Cancer.

[25]  J. Sprent,et al.  Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes , 2006, Science.

[26]  M. Jakóbisiak,et al.  Interleukin 12: still a promising candidate for tumor immunotherapy? , 2014, Cancer Immunology, Immunotherapy.

[27]  W. Leonard,et al.  New insights into the regulation of T cells by γc family cytokines , 2009, Nature Reviews Immunology.

[28]  H. Wong,et al.  Novel Human Interleukin-15 Agonists , 2009, The Journal of Immunology.

[29]  P. Kristjansen,et al.  A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer , 2012, British Journal of Cancer.

[30]  S. Riddell,et al.  Safety and immunologic effects of IL-15 administration in nonhuman primates. , 2009, Blood.

[31]  M. Smyth,et al.  Interleukin 21: combination strategies for cancer therapy , 2008, Nature Reviews Drug Discovery.

[32]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[33]  B. Curti.  Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma , 2006, Expert review of anticancer therapy.

[34]  A. Sher,et al.  T-bet is rapidly induced by interferon-γ in lymphoid and myeloid cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Krupke,et al.  IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. , 1997, Cellular immunology.

[36]  F. Claas,et al.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia , 2016, Science Translational Medicine.

[37]  T. Waldmann.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design , 2006, Nature Reviews Immunology.

[38]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Michelle M. Sandau,et al.  Cutting Edge: Transpresentation of IL-15 by Bone Marrow-Derived Cells Necessitates Expression of IL-15 and IL-15Rα by the Same Cells1 , 2004, The Journal of Immunology.

[40]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[41]  R. Paxton,et al.  Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling* , 1997, The Journal of Biological Chemistry.

[42]  J. Manning,et al.  Treatment of hairy cell leukemia with recombinant alpha-interferon. , 1986, Blood.

[43]  L. Radvanyi,et al.  The IL-2 cytokine family in cancer immunotherapy. , 2014, Cytokine & growth factor reviews.

[44]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Constantinescu,et al.  Role of interferon alpha/beta receptor chain 1 in the structure and transmembrane signaling of the interferon alpha/beta receptor complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Greil,et al.  Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. , 2000, Blood.

[47]  Jamie B. Spangler,et al.  Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. , 2015, Immunity.

[48]  T. Waldmann,et al.  Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia. , 2012, Blood.

[49]  W. Stemmer.  Rapid evolution of a protein in vitro by DNA shuffling , 1994, Nature.

[50]  C. Lamers,et al.  Activation of the immune system of cancer patients by continuous i.v. recombinant IL‐2 (rIL‐2) therapy is dependent on dose and schedule of rIL‐2 , 1993, Clinical and experimental immunology.

[51]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[52]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Tarhini,et al.  Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. , 2015, Seminars in oncology.

[54]  J. Darnell,et al.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.

[55]  T. Waldmann,et al.  Interleukin-15 biology and its therapeutic implications in cancer. , 2012, Trends in pharmacological sciences.

[56]  T. Waldmann.  The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. , 1986, Science.

[57]  J. Briones,et al.  NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. , 2008, Experimental hematology.

[58]  T. Waldmann,et al.  Augmented IL-15Rα Expression by CD40 Activation Is Critical in Synergistic CD8 T Cell-Mediated Antitumor Activity of Anti-CD40 Antibody with IL-15 in TRAMP-C2 Tumors in Mice , 2012, The Journal of Immunology.

[59]  A. Chang,et al.  A phase I clinical trial utilizing autologous tumor-infiltrating lymphocytes in patients with primary hepatocellular carcinoma , 2015, Oncotarget.

[60]  L. Khawli,et al.  Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. , 2003, Blood.

[61]  T. Waldmann,et al.  IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection , 2014, Proceedings of the National Academy of Sciences.

[62]  S. Rosenberg,et al.  IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory Cells , 2006, Journal of immunotherapy.

[63]  J. Becker,et al.  An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[64]  G. Dranoff,et al.  Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.

[65]  T. Waldmann,et al.  IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. , 2011, Blood.

[66]  D. Longo,et al.  Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity. , 2015, Immunity.

[67]  W. Linehan,et al.  Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.

[68]  T. Waldmann,et al.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. , 2017, Annual review of immunology.

[69]  A. Rotte,et al.  Immunotherapy of melanoma: Present options and future promises , 2015, Cancer and Metastasis Reviews.

[70]  S. Loisel,et al.  Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse , 2014, mAbs.

[71]  N. Agarwal,et al.  Immunotherapy of advanced renal cell carcinoma: Current and future therapies , 2016, Human vaccines & immunotherapeutics.

[72]  Patricia A. Young,et al.  Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. , 2014, Seminars in oncology.

[73]  T. Waldmann,et al.  Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. , 2011, Blood.

[74]  P. Morrissey,et al.  Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice , 2000, The Journal of experimental medicine.

[75]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[76]  M. Ratain,et al.  Treatment of hairy cell leukemia with recombinant alpha 2 interferon. , 1985, Blood.

[77]  R. Junghans,et al.  Phase I Trial of Anti‐PSMA Designer CAR‐T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2‐T Cell Pharmacodynamics as a Determinant of Clinical Response , 2016, The Prostate.

[78]  G. Lesinski,et al.  Immunomodulatory cytokines as therapeutic agents for melanoma. , 2011, Immunotherapy.

[79]  Jamie B. Spangler,et al.  Insights into cytokine-receptor interactions from cytokine engineering. , 2015, Annual review of immunology.

[80]  C. Mackall,et al.  Modulating T‐cell homeostasis with IL‐7: preclinical and clinical studies , 2009, Journal of internal medicine.

[81]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[82]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[83]  E. Jonasch,et al.  Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. , 2001, The oncologist.

[84]  W. Leonard,et al.  Interleukin-21: a double-edged sword with therapeutic potential , 2014, Nature Reviews Drug Discovery.

[85]  D. Lin,et al.  Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases , 2007, Proceedings of the National Academy of Sciences.